SCHEMBL976452

SCHEMBL976452

CNC(=O)C(=O)OC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphonic Acid SCHEMBL11023728 0.89 TET2 (0.39)
SCHEMBL21848012 0.80 ALDH1A1 (0.32)
SCHEMBL21602187 0.77 ALDH1A1 (0.36)
SCHEMBL26883233 0.75
SCHEMBL2239024 0.73
SCHEMBL8295 0.73
SCHEMBL6950834 0.73 ALDH1A1 (0.56)
SCHEMBL28763645 0.73
SCHEMBL22295830 0.73 ALDH1A1 (0.33)
SCHEMBL21594961 0.72 ALDH1A1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727537-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF Adaxion Therapeutics, Inc. (US) 2026-04-22 EP disclosed
US-20250064941-A1 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF ADAXION THERAPEUTICS, INC. 2025-02-27 US disclosed
WO-2024259007-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF OSPREY BIOPHARMACEUTICALS, INC. (US) 2024-12-19 WO disclosed
CN-109311848-A Novel heterocyclic derivatives useful as SHP2 inhibitors 北京加科思新药研发有限公司 2019-02-05 CN disclosed
CN-105246473-B Fe (III) complex compound for the treatment of and prevention for iron deficiency symptoms and hypoferric anemia 维福(国际)股份有限公司 2018-07-13 CN disclosed
US-9920050-B2 Fused heterocyclic compound and pest control use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-03-20 US disclosed
US-9920050-B2 Fused heterocyclic compound and pest control use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-03-20 US disclosed
US-20170008918-A1 NOVEL CYP-EICOSANOID DERIVATIVES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-01-12 US disclosed
US-20160368915-A1 FUSED HETEROCYCLIC COMPOUND AND PEST CONTROL USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-12-22 US disclosed
US-20160368915-A1 FUSED HETEROCYCLIC COMPOUND AND PEST CONTROL USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-12-22 US disclosed
US-20070021398-A1 Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-25 US disclosed
EP-1740551-A1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR Takeda Pharmaceutical Company Limited (JP) 2007-01-10 EP disclosed
WO-2005105760-A1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-11-10 WO disclosed
EP-1303262-A2 USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS ELI LILLY AND COMPANY (US) 2003-04-23 EP disclosed
EP-1073440-A4 sPLA 2 INHIBITOR ESTER LILLY CO ELI (US) 2002-07-17 EP disclosed
WO-2002005796-A2 USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS ELI LILLY AND COMPANY (US) 2002-01-24 WO disclosed
EP-1073440-A1 sPLA 2 INHIBITOR ESTERS ELI LILLY AND COMPANY (US) 2001-02-07 EP disclosed
WO-1999056752-A1 sPLA2 INHIBITOR ESTER ELI LILLY AND COMPANY (US) 1999-11-11 WO disclosed
EP-0127847-A1 7-Oxo-4-thia-1-azabicyclo(3.2.0)hept-2-ene derivatives HOECHST UK LIMITED (GB) 1984-12-12 EP disclosed
US-4006163-A POLYESTERS CIBA-GEIGY CORPORATION (US) 1977-02-01 US disclosed